Biocept - BIOC Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BIOC shares.
View BIOC analyst ratings or view top-rated stocks.

1 brokerages have issued twelve-month target prices for Biocept's shares. Their BIOC share price forecasts range from $4.00 to $4.00. On average, they expect the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 421.9% from the stock's current price.
View analysts price targets for BIOC or view top-rated stocks among Wall Street analysts.

Biocept's stock was trading at $3.62 at the beginning of 2022. Since then, BIOC stock has decreased by 78.8% and is now trading at $0.7665.
View the best growth stocks for 2022 here.

Biocept saw a decline in short interest in November. As of November 15th, there was short interest totaling 63,500 shares, a decline of 19.2% from the October 31st total of 78,600 shares. Based on an average daily trading volume, of 49,800 shares, the days-to-cover ratio is currently 1.3 days.
View Biocept's Short Interest.

Biocept, Inc. (NASDAQ:BIOC) announced its quarterly earnings data on Monday, November, 15th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by $0.06. The medical research company had revenue of $17.47 million for the quarter, compared to the consensus estimate of $16.87 million. Biocept had a negative net margin of 32.99% and a negative trailing twelve-month return on equity of 49.18%. During the same quarter in the previous year, the company earned ($0.43) earnings per share.

Biocept shares reverse split on Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 4th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

4 employees have rated Biocept Chief Executive Officer Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among the company's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Biocept to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Biocept's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.62%). Insiders that own company stock include David F Hale and David F Hale.
View institutional ownership trends.

Shares of BIOC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIOC stock can currently be purchased for approximately $0.77.

Biocept (NASDAQ:BIOC) has a market capitalization of $13.08 million and generates $61.25 million in revenue each year. The medical research company earns $-2,820,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis.

The company employs 104 workers across the globe.

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The official website for the company is www.biocept.com. The medical research company can be reached via phone at (858) 320-8200, via email at ir@biocept.com, or via fax at 858-320-8225.